Peroxisome proliferator-activated receptors and acute lung injury

Current Opinion in Pharmacology

Volumn 6, Issue 3, 2006, Pages 263-270

  Cuzzocrea, Salvatore ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; FIBRIC ACID DERIVATIVE; GW 7647; HORMONE RECEPTOR; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; PIRINIXIC ACID; RETINOID; ROSIGLITAZONE; STEROID RECEPTOR; THYROID HORMONE RECEPTOR; TROGLITAZONE; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ANTIINFLAMMATORY ACTIVITY; CELL PROLIFERATION; HUMAN; ISCHEMIA; LUNG EDEMA; LUNG INSUFFICIENCY; LUNG TRANSPLANTATION; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN FAMILY; REPERFUSION INJURY; REVIEW; SEPTIC SHOCK;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; HUMANS; LIGANDS; PPAR ALPHA; PPAR GAMMA; PROSTAGLANDIN D2; RESPIRATORY DISTRESS SYNDROME, ADULT; THIAZOLIDINEDIONES;

EID: 33646471976     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.01.008     Document Type: Review

References (46)

1. Murphy G.J., and Holder J.C. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 21 (2000) 469-474
2. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 129 (2000) 823-834
3. Clark R.B. The role of PPARs in inflammation and immunity. J Leukoc Biol 71 (2002) 388-400
4. Sher T., Yi H.F., McBride O.W., and Gonzalez F.J. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32 (1993) 5598-5604
5. Tontonoz P., Hu E., Graves R.A., Budavari A.I., and Spiegelman B.M. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8 (1994) 1224-1234
6. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
7. Ricote M., Huang J., Fajas L., Li A., Welch J., and Najib J. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 95 (1998) 7614-7619
8. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., and Evans R.M. 15-deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83 (1995) 803-812
9. Powell W.S. 15-deoxy-delta12,14-PGJ2: endogenous PPARgamma ligand or minor eicosanoid degradation product?. J Clin Invest 112 (2003) 828-830
10. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., and Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7 (2001) 48-52
11. Willson T.M., Brown P.J., Sternbach D.D., and Henke B.R. The PPARs: from orphan receptors to drug discovery. J Med Chem 43 (2000) 527-550
12. Colville-Nash P.R., Qureshi S.S., Willis D., and Willoughby D.A. Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1. J Immunol 161 (1998) 978-984
13. Lee H., Shi W., Tontonoz P., Wang S., Subbanagounder G., Hedrick C.C., Hama S., Borromeo C., Evans R.M., Berliner J.A., et al. Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res 87 (2000) 516-521
14. Sugiyama H., Nonaka T., Kishimoto T., Komoriya K., Tsuji K., and Nakahata T. Peroxisome proliferator-activated receptors are expressed in human cultured mast cells: a possible role of these receptors in negative regulation of mast cell activation. Eur J Immunol 30 (2000) 3363-3370
15. Sugiyama H., Nonaka T., Kishimoto T., Komoriya K., Tsuji K., and Nakahata T. Peroxisome proliferator-activated receptors are expressed in mouse bone marrow-derived mast cells. FEBS Lett 467 (2000) 259-262
16. Chinetti G., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49 (2000) 497-505
17. Lovett-Racke A.E., Hussain R.Z., Northrop S., Choy J., Rocchini A., Matthes L., Chavis J.A., Diab A., Drew P.D., and Racke M.K. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol 172 (2004) 5790-5798
18. Genovese T., Mazzon E., Di Paola R., Cannavo G., Muia C., Bramanti P., and Cuzzocrea S. Role of endogenous ligands for the peroxisome proliferators activated receptors alpha in the secondary damage in experimental spinal cord trauma. Exp Neurol 194 (2005) 267-278
19. Okamoto H., Iwamoto T., Kotake S., Momohara S., Yamanaka H., and Kamatani N. Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol 23 (2005) 323-330
20. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., Fruchart J.C., Tedgui A., Haegeman G., and Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 274 (1999) 32048-32054
21. Delerive P., Gervois P., Fruchart J.C., and Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 275 (2000) 36703-36707
22. Dyroy E., Yndestad A., Ueland T., Halvorsen B., Damas J.K., Aukrust P., and Berge R.K. Anti-inflammatory effects of tetradecylthioacetic acid involve both peroxisome proliferator-activated receptor alpha-dependent and -independent pathways. Arterioscler Thromb Vasc Biol 25 (2005) 1364-1369
23. Genovese T., Mazzon E., Di Paola R., Muia C., Crisafulli C., Caputi A.P., and Cuzzocrea S. Role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor alpha in the development of bleomycin-induced lung injury. Shock 24 (2005) 547-555
24. Cuzzocrea S, Mazzon E, Di Paola R, Peli A, Bonato A, Britti D, Genovese T, Mui C, Crisafulli C, Caputi AP. The role of the peroxisome proliferator-activated receptor-{alpha} (PPAR-{alpha}) in the regulation of acute inflammation. J Leukoc Biol. 2006, Feb 24; [Epub ahead of print].
25. Kawahito Y., Kondo M., Tsubouchi Y., Hashiramoto A., Bishop-Bailey D., Inoue K., Kohno M., Yamada R., Hla T., and Sano H. 15-Deoxy-delta (12,14)-PGJ(2) induces synoviocyte apoptosis and sup-presses adjuvant-induced arthritis in rats. J. Clin. Investig 106 (2000) 189-197
26. Su C.G., Wen X., Bailey S.T., Jiang W., Rangwala S.M., Keilbaugh S.A., Flanigan A., Murthy S., Lazar M.A., and Wu G.D. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J Clin Investig 104 (1999) 383-389
27. Standiford T.J., Keshamouni V.G., and Reddy R.C. Peroxisome proliferator-activated receptor-{gamma} as a regulator of lung inflammation and repair. Proc Am Thorac Soc 2 (2005) 226-231
28. Keshamouni V.G., Arenberg D.A., Reddy R.C., Newstead M.J., Anthwal S., and Standiford T.J. PPAR-γ activation inhibits angiogenesis by blocking ELR+ CXC chemokine production in non small cell lung cancer. Neoplasia 7 (2005) 294-301
29. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
30. Keshamouni V.G., Reddy R.C., Arenberg D.A., Joel B., Thannickal V.J., Kalemkerian G.P., and Standiford T.J. Peroxisome proliferator-activated receptor-γ activation inhibits tumour progression in non-small-cell lung cancer. Oncogene 23 (2004) 100-108
31. Cuzzocrea S., Pisano B., Dugo L., Ianaro A., Maffia P., Patel N.S., Di Paola R., Ialenti A., Genovese T., Chatterjee P.K., et al. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol 483 (2004) 79-93
32. Cuzzocrea S., Wayman N.S., Mazzon E., Dugo L., Di Paola R., Serraino I., Britti D., Chatterjee P.K., Caputi A.P., and Thiemermann C. The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) attenuates the development of acute and chronic inflammation. Mol Pharmacol 61 (2002) 997-1007
33. Ando M., Murakami Y., Kojima F., Endo H., Kitasato H., Hashimoto A., Kobayashi H., Majima M., Inoue M., Kondo H., et al. Retrovirally introduced prostaglandin D2 synthase suppresses lung injury induced by bleomycin. Am J Respir Cell Mol Biol 28 (2003) 582-591
34. Inoue K.I., Takano H., Yanagisawa R., Morita M., Ichinose T., Sadakane K., Yoshino S., Yamaki K., Kumagai Y., Uchiyama K., et al. Effects of 15-deoxy-Δ12,14-prostaglandin J2 on acute lung injury induced by lipopolysaccharide in mice. Eur J Pharmacol 481 (2003) 261-269
35. Liu S.F., Ye X., and Malik A.B. Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents in vivo expression of proinflammatory genes. Circulation 100 (1999) 1330-1337
36. Ishii H., Ishibashi M., Takayama M., Nishida T., and Yoshida M. The role of cytokine-induced neutrophil chemoattractant-1 in neutrophil-mediated remote lung injury after intestinal ischaemia/reperfusion in rats. Respirology 5 (2000) 325-331
37. Okada M., Yan S.F., and Pinsky D.J. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. FASEB J 16 (2002) 1861-1868
38. Guyton K., Zingarelli B., Ashton S., Teti G., Tempel G., and Reilly C. Peroxisome proliferator-activated receptor-gamma agonists modulate macrophage activation by Gram-negative and Gram-positive bacterial stimuli. Shock 20 (2003) 56-62
39. Collin M., and Thiemermann C. The PPAR-gamma ligand 15-deoxy(delta12,14) prostaglandin J2 reduces the liver injury in endotoxic shock. Eur J Pharmacol 476 (2003) 257-258
40. Collin M., Patel N.S., Dugo L., and Thiemermann C. Role of peroxisome proliferator-activated receptor-gamma in the protection afforded by 15-deoxydelta12,14 prostaglandin J2 against the multiple organ failure caused by endotoxin. Crit Care Med 32 (2004) 826-831
41. Dugo L., Collin M., Cuzzocrea S., and Thiemermann C. 15d-prostaglandin J(2) reduces multiple organ failure caused by wall-fragment of Gram-positive and Gram-negative bacteria. Eur J Pharmacol 498 (2004) 295-301
42. Cuzzocrea S., Pisano B., Dugo L., Ianaro A., Patel N.S., and Di Paola R. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med 32 (2004) 457-466
43. Marzocco S., Di Paola R., Mazzon E., Genovese T., Britti D., Pinto A., Autore G., and Cuzzocrea S. The cyclopentenone prostaglandin 15-deoxydelta(12,14)-prostaglandin J2 attenuates the development of zymosan-induced shock. Intensive Care Med 31 (2005) 693-700
44. Zingarelli B., Sheehan M., Hake P.W., O'Connor M., Denenberg A., and Cook J.A. Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol 171 (2003) 6827-6837
45. Abdelrahman M., Collin M., and Thiemermann C. The peroxisome proliferator-activated receptor-gamma ligand 15-deoxyD12,14 prostaglandin J2 reduces the organ injury in hemorrhagic shock. Shock 22 (2004) 555-561
46. Collin M., Abdelrahman M., and Thiemermann C. Endogenous ligands of PPAR-gamma reduce the liver injury in haemorrhagic shock. Eur J Pharmacol 486 (2004) 233-235